The clinicopathologic features of 22 ARL patients with meningeal disease treated with different intrathecal regimens
. | All . | Methorexate/cytarabine . | DepoCyte . | P . |
|---|---|---|---|---|
| No. | 22* | 17 | 5 | NA |
| Male, no. (%) | 19 (86) | 15 (88) | 4 (80) | χ2 .64 |
| Mean age, y (range) | 43 (29-60) | 42 (29-60) | 37 (29-47) | MW .05 |
| Median CD4/mm3 (IQR)† | 173 (150) | 173 (156) | 173 (136) | MW .81 |
| CD4 < 100/mm3, no. (%) | 4 (18) | 3 (1) | 1 (20) | χ2 .90 |
| Prior ADI, no. (%) | 2 (9) | 2 (12) | 0 (0) | χ2 .42 |
| On HAART at NHL diagnosis, no. (%) | 15 (68) | 12 (71) | 3 (60) | χ2 .65 |
| Viral load less than 50 copies/mL, no. (%) | 3/21 (14) | 3/16 (19) | 0/5 (0) | χ2 .29 |
| Bone marrow involved by NHL, no. (%) | 11 (50) | 9 (53) | 2 (40) | χ2 .26 |
| Burkitt histology, no. (%) | 8 (36) | 7 (41) | 1 (20) | χ2 .39 |
| ECOG PS, no. (%) | χ2 .77 | |||
| 1 | 6 (27) | 5 (29) | 1 (20) | |
| 2 | 8 (36) | 6 (35) | 2 (40) | |
| 3 | 2 (9) | 2 (12) | 0 (0) | |
| 4 | 6 (27) | 4 (23) | 2 (40) | |
| IPI group, no. (%) | χ2 .85 | |||
| LI | 3 (14) | 2 (12) | 1 (20) | |
| HI | 6 (27) | 5 (29) | 1 (20) | |
| H | 13 (59) | 10 (59) | 3 (60) | |
| Median CSF protein, mg/L (IQR) | 0.70 (1.5) | 0.74 (1.5) | 0.58 (1.4) | MW .59 |
. | All . | Methorexate/cytarabine . | DepoCyte . | P . |
|---|---|---|---|---|
| No. | 22* | 17 | 5 | NA |
| Male, no. (%) | 19 (86) | 15 (88) | 4 (80) | χ2 .64 |
| Mean age, y (range) | 43 (29-60) | 42 (29-60) | 37 (29-47) | MW .05 |
| Median CD4/mm3 (IQR)† | 173 (150) | 173 (156) | 173 (136) | MW .81 |
| CD4 < 100/mm3, no. (%) | 4 (18) | 3 (1) | 1 (20) | χ2 .90 |
| Prior ADI, no. (%) | 2 (9) | 2 (12) | 0 (0) | χ2 .42 |
| On HAART at NHL diagnosis, no. (%) | 15 (68) | 12 (71) | 3 (60) | χ2 .65 |
| Viral load less than 50 copies/mL, no. (%) | 3/21 (14) | 3/16 (19) | 0/5 (0) | χ2 .29 |
| Bone marrow involved by NHL, no. (%) | 11 (50) | 9 (53) | 2 (40) | χ2 .26 |
| Burkitt histology, no. (%) | 8 (36) | 7 (41) | 1 (20) | χ2 .39 |
| ECOG PS, no. (%) | χ2 .77 | |||
| 1 | 6 (27) | 5 (29) | 1 (20) | |
| 2 | 8 (36) | 6 (35) | 2 (40) | |
| 3 | 2 (9) | 2 (12) | 0 (0) | |
| 4 | 6 (27) | 4 (23) | 2 (40) | |
| IPI group, no. (%) | χ2 .85 | |||
| LI | 3 (14) | 2 (12) | 1 (20) | |
| HI | 6 (27) | 5 (29) | 1 (20) | |
| H | 13 (59) | 10 (59) | 3 (60) | |
| Median CSF protein, mg/L (IQR) | 0.70 (1.5) | 0.74 (1.5) | 0.58 (1.4) | MW .59 |
NA indicates not applicable. MW, Mann-Whitney test; IQR, interquartile range; ADI, AIDS-defining illness; ECOG PS, Eastern Cooperative Oncology Group performance status; and IPI, International Prognostic Index (low-intermediate [LI], high- intermediate [HI], and high [H]).
These 22 patients received systemic chemotherapy with alternating weekly BEMOP/CA (n = 4), monthly CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (n = 1), or infusional CDE (cyclophosphamide, doxorubicin, and etoposide) (n = 17) as previously described15-17
CD4 subset analysis (cells/mm3) was performed using whole blood stained with murine antihuman monoclonal antibodies to CD4 (TetraOne; Beckman Coulter, High Wycombe, United Kingdom) and plasma viral loads (Quantiplex HIV RNA 3.0; Chiron, Halstead, United Kingdom) were recorded since 1998 with a lower limit of detection of 50 copies/mL. CSF protein was measured using the PRM assay (Sigma Aldrich, Poole, United Kingdom) with an upper limit of normal of 450 mg/L; cytospins were undertaken using standard light microscopy to detect cells. Comparison of variables between groups was by χ2 test for nominal variables and MW U test for nonparametric variables; all P values presented are 2-sided